Artemisinin — Qinghaosu (Sesquiterpene Endoperoxide · Antimalarial · Antiviral)
| Compound | Artemisinin (Qinghaosu) |
| Chemical class | Terpenoid — Sesquiterpene Endoperoxide Lactone (Unique trioxane ring) |
| CAS | 63968-64-9 |
| Primary source | Artemisia annua (sweet wormwood / Qing Hao) |
| Key applications | Antimalarial (WHO-approved), antiviral, anticancer research, anti-inflammatory |
| Claim strength | High (antimalarial) / Moderate (other) |
| Typical form | Artemisinin isolate; Artemisia annua extract (standardised to artemisinin); ACT pharmaceutical combinations |
| Buy from Herbuno |
Name origin: From Artemisia annua (Qing Hao in TCM). The Chinese traditional name “Qinghaosu” means “substance from Qing Hao.” Its discovery and development into the world’s most effective malaria treatment earned Tu Youyou the Nobel Prize in Physiology or Medicine in 2015. Traditional use: Artemisia annua (Qing Hao) has been used in Chinese medicine since at least 168 BCE (documented in the Mawangdui Silk Texts) for fevers and malaria-like illnesses. The 4th-century TCM text A Handbook of Prescriptions for Emergency by Ge Hong specifically described soaking Qing Hao in cold water and squeezing it for fever treatment — the cold-water extraction described prevented the heat-sensitive artemisinin from degrading, a detail that was crucial to Tu Youyou’s laboratory extraction breakthrough in 1972. Research trajectory: Artemisinin and its semi-synthetic derivatives (artesunate, artemether, dihydroartemisinin) are WHO-approved as first-line malaria treatments in artemisinin-based combination therapies (ACTs). Additional research has established antiviral activity (SARS-CoV-2, CMV, hepatitis B), antiprotozoal activity (toxoplasmosis, leishmaniasis), and extensive antiproliferative/anticancer preclinical evidence. Commercial source: Artemisia annua (Sweet Wormwood) Extract Powder from Herbuno. See sourcing options below.
Evidence for Artemisinin Applications
Antimalarial — WHO first-line treatment: Artemisinin-based combination therapies (ACTs) are the WHO-recommended first-line treatment for uncomplicated Plasmodium falciparum malaria globally. Artemisinin’s unique endoperoxide bridge (trioxane ring) is activated by haem iron inside malaria-infected red blood cells, generating free radicals that kill the parasite with high selectivity. Multiple large-scale clinical trials confirm >95% cure rates for uncomplicated malaria. Claim strength: High (pharmaceutical approval; extensive RCT data).
Antiviral activity: Artemisinin and artesunate inhibit SARS-CoV-2 replication in cell models (inhibiting viral protease and replication complex). Anti-CMV (cytomegalovirus) activity is well-established and clinically investigated. Anti-HBV (hepatitis B) activity is documented. Early-stage human data for artesunate in CMV infection in immunocompromised patients are promising. Claim strength: Moderate.
Antiproliferative / anticancer (preclinical): Artemisinin and its derivatives induce cancer cell apoptosis via the same iron-activated free radical mechanism that kills malaria parasites — cancer cells accumulate iron (high transferrin receptor expression) and are preferentially susceptible. Extensive preclinical data across multiple cancer cell lines. Small human case series and pilot studies. Claim strength: Moderate (preclinical convergent; human data very limited — not approved cancer treatment).
Anti-inflammatory: Artemisinin inhibits NF-κB, reduces TNF-α, IL-6, and IL-1β, and modulates T-cell responses. Used in a small number of human studies for autoimmune conditions (lupus, rheumatoid arthritis) with promising results. Claim strength: Moderate.
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Pharmaceutical malaria treatment (ACT): artemisinin 50–200 mg/day equivalent in combination with partner drugs (lumefantrine, amodiaquine, mefloquine) for 3-day treatment courses — these are prescription pharmaceutical uses requiring drug regulatory approval, not supplement applications. For supplement and non-pharmaceutical contexts: Artemisia annua extract at 100–500 mg/day (standardised to artemisinin content) is used in integrative oncology and broad-spectrum antiviral contexts. Specify artemisinin content by HPLC on CoA — artemisinin content in commercial A. annua extract varies from 0.1–1.5% depending on extraction method and plant source.
IMPORTANT: Artemisinin is heat-labile — hot water extraction destroys artemisinin (consistent with Tu Youyou’s cold-water extraction breakthrough). Specify cold-solvent extraction (ethanol or cold water) for artemisinin-preserved extracts. Standard hot water decoction of A. annua delivers artabsin, flavonoids, and polysaccharides but negligible artemisinin. Artemisinin resistance is an emerging concern in Southeast Asia for malaria treatment — a public health issue not directly relevant to supplement applications but important context for formulator education.
Frequently Asked Questions — Artemisinin
Why did Tu Youyou win the Nobel Prize for artemisinin?
Tu Youyou’s discovery emerged from a secret Chinese military research programme (Project 523) initiated in 1967 during the Vietnam War, when malaria was killing more Vietnamese soldiers than combat. She screened over 2,000 traditional Chinese herbal preparations, identified Qing Hao (Artemisia annua) as a lead candidate from a 4th-century text, and crucially used cold ethanol extraction (suggested by the historical text’s cold-water method) rather than hot decoction — preserving the heat-labile artemisinin. The discovery transformed malaria treatment globally, saving millions of lives. The Nobel Committee awarded the prize in 2015 — 43 years after the discovery — recognising the compound’s extraordinary clinical impact.
Can artemisinin supplements be used as anti-cancer treatment?
No — artemisinin supplements should not be positioned or used as cancer treatment. While the preclinical antiproliferative evidence is compelling and mechanistically plausible, human clinical trial evidence for cancer treatment is very limited and no regulatory approval exists. Patients replacing conventional cancer therapy with artemisinin supplements risk serious harm from untreated cancer. The integrative oncology context — where artemisinin is used as an adjunct alongside conventional treatment under physician supervision — is where the research is most developed, but this requires medical supervision and is distinct from over-the-counter supplement use.
What is the difference between artemisinin, artesunate, and artemether?
Artemisinin is the natural compound from A. annua. Artesunate (water-soluble hemisuccinate) and artemether (lipid-soluble methyl ether) are semi-synthetic derivatives with improved pharmacokinetics: better bioavailability, faster action, and longer half-life than natural artemisinin. Dihydroartemisinin (DHA) is the active metabolite of both. ACT pharmaceutical treatments use these derivatives, not natural artemisinin. A. annua botanical extract delivers natural artemisinin alongside other phytochemicals.
Is there any risk of malaria drug resistance from using artemisinin supplements?
This is a legitimate public health concern. Artemisinin resistance in Plasmodium falciparum malaria, now documented across Southeast Asia, is linked to sub-therapeutic artemisinin exposure. Using botanical A. annua preparations (delivering low, non-standardised artemisinin doses) for malaria prevention in endemic areas could theoretically contribute to resistance selection. WHO guidance recommends against using non-pharmaceutical artemisinin preparations for malaria prophylaxis or treatment for this reason. This concern is specific to malaria-endemic use; supplement use in non-endemic populations for antiviral or general wellness purposes does not carry this specific public health risk.
Related compounds: Artabsin, Thymoquinone, Andrographolide, Betulinic Acid
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery